ID   XPF_HUMAN               Reviewed;         916 AA.
AC   Q92889; A5PKV6; A8K111; O00140; Q8TD83;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   28-JUN-2023, entry version 221.
DE   RecName: Full=DNA repair endonuclease XPF;
DE            EC=3.1.-.- {ECO:0000269|PubMed:10413517};
DE   AltName: Full=DNA excision repair protein ERCC-4 {ECO:0000303|PubMed:8887684};
DE   AltName: Full=DNA repair protein complementing XP-F cells {ECO:0000303|PubMed:8797827};
DE   AltName: Full=Xeroderma pigmentosum group F-complementing protein {ECO:0000303|PubMed:8797827};
GN   Name=ERCC4 {ECO:0000303|PubMed:8887684, ECO:0000312|HGNC:HGNC:3436};
GN   Synonyms=ERCC11, XPF {ECO:0000303|PubMed:8887684};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8887684; DOI=10.1128/mcb.16.11.6553;
RA   Brookman K.W., Lamerdin J.E., Thelen M.P., Hwang M., Reardon J.T.,
RA   Sancar A., Zhou Z.-Q., Walter C.A., Parris C.N., Thompson L.H.;
RT   "ERCC4 (XPF) encodes a human nucleotide excision repair protein with
RT   eukaryotic recombination homologs.";
RL   Mol. Cell. Biol. 16:6553-6562(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-168; SER-379; GLN-415;
RP   PRO-662; THR-706; VAL-873 AND GLY-875.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLN-415.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-916 (ISOFORM 1), FUNCTION, VARIANT ASP-703,
RP   AND VARIANT XP-F TRP-799.
RC   TISSUE=Fibroblast;
RX   PubMed=8797827; DOI=10.1016/s0092-8674(00)80155-5;
RA   Sijbers A.M., de Laat W.L., Ariza R.R., Biggerstaff M., Wei Y.-F.,
RA   Moggs J.G., Carter K.C., Shell B.K., Evans E., de Jong M.C., Rademakers S.,
RA   de Rooij J., Jaspers N.G.J., Hoeijmakers J.H.J., Wood R.D.;
RT   "Xeroderma pigmentosum group F caused by a defect in a structure-specific
RT   DNA repair endonuclease.";
RL   Cell 86:811-822(1996).
RN   [7]
RP   REVIEW ON VARIANTS XP-F.
RX   PubMed=10447254;
RX   DOI=10.1002/(sici)1098-1004(1999)14:1<9::aid-humu2>3.0.co;2-6;
RA   Cleaver J.E., Thompson L.H., Richardson A.S., States J.C.;
RT   "A summary of mutations in the UV-sensitive disorders: xeroderma
RT   pigmentosum, Cockayne syndrome, and trichothiodystrophy.";
RL   Hum. Mutat. 14:9-22(1999).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND INTERACTION WITH ERCC1.
RX   PubMed=10413517; DOI=10.1021/bi990591+;
RA   McCutchen-Maloney S.L., Giannecchini C.A., Hwang M.H., Thelen M.P.;
RT   "Domain mapping of the DNA binding, endonuclease, and ERCC1 binding
RT   properties of the human DNA repair protein XPF.";
RL   Biochemistry 38:9417-9425(1999).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11790111; DOI=10.1021/bi011614z;
RA   Kumaresan K.R., Hwang M., Thelen M.P., Lambert M.W.;
RT   "Contribution of XPF functional domains to the 5' and 3' incisions produced
RT   at the site of a psoralen interstrand cross-link.";
RL   Biochemistry 41:890-896(2002).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SLX4.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [11]
RP   INTERACTION WITH SLX4.
RX   PubMed=19596236; DOI=10.1016/j.cell.2009.06.029;
RA   Fekairi S., Scaglione S., Chahwan C., Taylor E.R., Tissier A., Coulon S.,
RA   Dong M.-Q., Ruse C., Yates J.R. III, Russell P., Fuchs R.P., McGowan C.H.,
RA   Gaillard P.-H.L.;
RT   "Human SLX4 is a Holliday junction resolvase subunit that binds multiple
RT   DNA repair/recombination endonucleases.";
RL   Cell 138:78-89(2009).
RN   [12]
RP   INTERACTION WITH SLX4.
RX   PubMed=19595721; DOI=10.1016/j.molcel.2009.06.020;
RA   Munoz I.M., Hain K., Declais A.-C., Gardiner M., Toh G.W.,
RA   Sanchez-Pulido L., Heuckmann J.M., Toth R., Macartney T., Eppink B.,
RA   Kanaar R., Ponting C.P., Lilley D.M.J., Rouse J.;
RT   "Coordination of structure-specific nucleases by human SLX4/BTBD12 is
RT   required for DNA repair.";
RL   Mol. Cell 35:116-127(2009).
RN   [13]
RP   INTERACTION WITH SLX4.
RX   PubMed=19595722; DOI=10.1016/j.molcel.2009.06.019;
RA   Andersen S.L., Bergstralh D.T., Kohl K.P., LaRocque J.R., Moore C.B.,
RA   Sekelsky J.;
RT   "Drosophila MUS312 and the vertebrate ortholog BTBD12 interact with DNA
RT   structure-specific endonucleases in DNA repair and recombination.";
RL   Mol. Cell 35:128-135(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-289, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   INTERACTION WITH ERCC1 AND SLX4.
RX   PubMed=25538220; DOI=10.15252/embj.201489184;
RA   Perez-Oliva A.B., Lachaud C., Szyniarowski P., Munoz I., Macartney T.,
RA   Hickson I., Rouse J., Alessi D.R.;
RT   "USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage
RT   responses.";
RL   EMBO J. 34:326-343(2015).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-500, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [19]
RP   FUNCTION, INTERACTION WITH ERCC1, ACETYLATION AT LYS-911, AND MUTAGENESIS
RP   OF LYS-911.
RX   PubMed=32034146; DOI=10.1038/s41467-020-14564-x;
RA   Wang J., He H., Chen B., Jiang G., Cao L., Jiang H., Zhang G., Chen J.,
RA   Huang J., Yang B., Zhou C., Liu T.;
RT   "Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and
RT   activation.";
RL   Nat. Commun. 11:786-786(2020).
RN   [20] {ECO:0007744|PDB:2A1J}
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 848-909 IN COMPLEX WITH ERCC1,
RP   DNA-BINDING, DOMAINS, AND SUBUNIT.
RX   PubMed=16076955; DOI=10.1073/pnas.0504341102;
RA   Tsodikov O.V., Enzlin J.H., Scharer O.D., Ellenberger T.;
RT   "Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA
RT   structure-specific endonuclease XPF-ERCC1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11236-11241(2005).
RN   [21] {ECO:0007744|PDB:1Z00}
RP   STRUCTURE BY NMR OF 834-916 IN COMPLEX WITH ERCC1, AND SUBUNIT.
RX   PubMed=16338413; DOI=10.1016/j.str.2005.08.014;
RA   Tripsianes K., Folkers G., Ab E., Das D., Odijk H., Jaspers N.G.,
RA   Hoeijmakers J.H., Kaptein R., Boelens R.;
RT   "The structure of the human ERCC1/XPF interaction domains reveals a
RT   complementary role for the two proteins in nucleotide excision repair.";
RL   Structure 13:1849-1858(2005).
RN   [22]
RP   VARIANT SER-379.
RX   PubMed=9485007;
RA   Shen M.R., Jones I.M., Mohrenweiser H.;
RT   "Nonconservative amino acid substitution variants exist at polymorphic
RT   frequency in DNA repair genes in healthy humans.";
RL   Cancer Res. 58:604-608(1998).
RN   [23]
RP   VARIANTS XP-F MET-225; TRP-454; GLN-490; LYS-502; ARG-513; THR-529;
RP   ALA-567; 605-VAL--GLY-611 DEL AND PRO-608.
RX   PubMed=9580660; DOI=10.1093/hmg/7.6.969;
RA   Matsumura Y., Nishigori C., Yagi T., Imamura S., Takebe H.;
RT   "Characterization of molecular defects in Xeroderma pigmentosum group F in
RT   relation to its clinically mild symptoms.";
RL   Hum. Mol. Genet. 7:969-974(1998).
RN   [24]
RP   VARIANT XP-F TRP-799.
RX   PubMed=9579555; DOI=10.1046/j.1523-1747.1998.00171.x;
RA   Sijbers A.M., van Voorst Vader P.C., Snoek J.W., Raams A., Jaspers N.G.J.,
RA   Kleijer W.J.;
RT   "Homozygous R788W point mutation in the XPF gene of a patient with
RT   xeroderma pigmentosum and late-onset neurologic disease.";
RL   J. Invest. Dermatol. 110:832-836(1998).
RN   [25]
RP   VARIANTS GLN-415; THR-576; THR-717 AND GLY-875.
RX   PubMed=10479728; DOI=10.1016/s1383-5726(99)00008-4;
RA   Fan F., Liu C., Tavare S., Arnheim N.;
RT   "Polymorphisms in the human DNA repair gene XPF.";
RL   Mutat. Res. 406:115-120(1999).
RN   [26]
RP   VARIANT XFEPS PRO-153.
RX   PubMed=17183314; DOI=10.1038/nature05456;
RA   Niedernhofer L.J., Garinis G.A., Raams A., Lalai A.S., Robinson A.R.,
RA   Appeldoorn E., Odijk H., Oostendorp R., Ahmad A., van Leeuwen W.,
RA   Theil A.F., Vermeulen W., van der Horst G.T.J., Meinecke P., Kleijer W.J.,
RA   Vijg J., Jaspers N.G.J., Hoeijmakers J.H.J.;
RT   "A new progeroid syndrome reveals that genotoxic stress suppresses the
RT   somatotroph axis.";
RL   Nature 444:1038-1043(2006).
RN   [27]
RP   VARIANTS FANCQ PRO-230 AND SER-689.
RX   PubMed=23623386; DOI=10.1016/j.ajhg.2013.04.002;
RA   Bogliolo M., Schuster B., Stoepker C., Derkunt B., Su Y., Raams A.,
RA   Trujillo J.P., Minguillon J., Ramirez M.J., Pujol R., Casado J.A.,
RA   Banos R., Rio P., Knies K., Zuniga S., Benitez J., Bueren J.A.,
RA   Jaspers N.G., Schaerer O.D., de Winter J.P., Schindler D., Surralles J.;
RT   "Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause
RT   Fanconi anemia.";
RL   Am. J. Hum. Genet. 92:800-806(2013).
RN   [28]
RP   VARIANTS XPF/CS ARG-236 AND TRP-589.
RX   PubMed=23623389; DOI=10.1016/j.ajhg.2013.04.007;
RA   Kashiyama K., Nakazawa Y., Pilz D.T., Guo C., Shimada M., Sasaki K.,
RA   Fawcett H., Wing J.F., Lewin S.O., Carr L., Li T.S., Yoshiura K., Utani A.,
RA   Hirano A., Yamashita S., Greenblatt D., Nardo T., Stefanini M.,
RA   McGibbon D., Sarkany R., Fassihi H., Takahashi Y., Nagayama Y.,
RA   Mitsutake N., Lehmann A.R., Ogi T.;
RT   "Malfunction of nuclease ERCC1-XPF results in diverse clinical
RT   manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and
RT   Fanconi anemia.";
RL   Am. J. Hum. Genet. 92:807-819(2013).
RN   [29]
RP   VARIANTS CYS-150; HIS-267 AND ALA-621, VARIANTS FANCQ SER-689 AND PHE-786,
RP   CHARACTERIZATION OF VARIANT CYS-150, CHARACTERIZATION OF VARIANTS FANCQ
RP   SER-689 AND PHE-786, AND FUNCTION.
RX   PubMed=24027083; DOI=10.1002/humu.22438;
RA   Osorio A., Bogliolo M., Fernandez V., Barroso A., de la Hoya M., Caldes T.,
RA   Lasa A., Ramon y Cajal T., Santamarina M., Vega A., Quiles F., Lazaro C.,
RA   Diez O., Fernandez D., Gonzalez-Sarmiento R., Duran M., Piqueras J.F.,
RA   Marin M., Pujol R., Surralles J., Benitez J.;
RT   "Evaluation of rare variants in the new fanconi anemia gene ERCC4 (FANCQ)
RT   as familial breast/ovarian cancer susceptibility alleles.";
RL   Hum. Mutat. 34:1615-1618(2013).
CC   -!- FUNCTION: Catalytic component of a structure-specific DNA repair
CC       endonuclease responsible for the 5-prime incision during DNA repair,
CC       and which is essential for nucleotide excision repair (NER) and
CC       interstrand cross-link (ICL) repair. {ECO:0000269|PubMed:10413517,
CC       ECO:0000269|PubMed:11790111, ECO:0000269|PubMed:19596235,
CC       ECO:0000269|PubMed:24027083, ECO:0000269|PubMed:32034146,
CC       ECO:0000269|PubMed:8797827}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10413517};
CC   -!- SUBUNIT: Heterodimer composed of ERCC1 and ERCC4/XPF (PubMed:10413517,
CC       PubMed:25538220, PubMed:32034146, PubMed:16076955, PubMed:16338413).
CC       Interacts with SLX4/BTBD12; this interaction is direct and links the
CC       ERCC1-ERCC4/XPF complex to SLX4, which may coordinate the action of the
CC       structure-specific endonuclease during DNA repair (PubMed:19596235,
CC       PubMed:19596236, PubMed:25538220, PubMed:19595721, PubMed:19595722).
CC       {ECO:0000269|PubMed:10413517, ECO:0000269|PubMed:16076955,
CC       ECO:0000269|PubMed:16338413, ECO:0000269|PubMed:19595721,
CC       ECO:0000269|PubMed:19595722, ECO:0000269|PubMed:19596235,
CC       ECO:0000269|PubMed:19596236, ECO:0000269|PubMed:25538220,
CC       ECO:0000269|PubMed:32034146}.
CC   -!- INTERACTION:
CC       Q92889; P07992: ERCC1; NbExp=13; IntAct=EBI-2370770, EBI-750962;
CC       Q92889; Q92889: ERCC4; NbExp=2; IntAct=EBI-2370770, EBI-2370770;
CC       Q92889; Q8IY92: SLX4; NbExp=10; IntAct=EBI-2370770, EBI-2370740;
CC       Q92889; O75410-7: TACC1; NbExp=3; IntAct=EBI-2370770, EBI-12007872;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:19596235}. Chromosome
CC       {ECO:0000269|PubMed:11790111}. Note=Localizes to sites of DNA damage.
CC       {ECO:0000269|PubMed:11790111}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92889-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92889-2; Sequence=VSP_056341, VSP_056342;
CC   -!- PTM: Acetylation at Lys-911 by KAT5 promotes interaction with ERCC1 by
CC       disrupting a salt bridge between Glu-907 and Lys-911, thereby exposing
CC       a second binding site for ERCC1 (PubMed:32034146). Deacetylated by
CC       SIRT1 (PubMed:32034146). {ECO:0000269|PubMed:32034146}.
CC   -!- DISEASE: Xeroderma pigmentosum complementation group F (XP-F)
CC       [MIM:278760]: An autosomal recessive pigmentary skin disorder
CC       characterized by solar hypersensitivity of the skin, high
CC       predisposition for developing cancers on areas exposed to sunlight and,
CC       in some cases, neurological abnormalities. The skin develops marked
CC       freckling and other pigmentation abnormalities. XP-F patients show a
CC       mild phenotype. {ECO:0000269|PubMed:10447254,
CC       ECO:0000269|PubMed:8797827, ECO:0000269|PubMed:9579555,
CC       ECO:0000269|PubMed:9580660}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: XFE progeroid syndrome (XFEPS) [MIM:610965]: A syndrome
CC       characterized by aged bird-like facies, lack of subcutaneous fat,
CC       dwarfism, cachexia and microcephaly. Additional features include sun-
CC       sensitivity from birth, learning disabilities, hearing loss, and visual
CC       impairment. {ECO:0000269|PubMed:17183314}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Xeroderma pigmentosum type F/Cockayne syndrome (XPF/CS)
CC       [MIM:278760]: A variant form of Cockayne syndrome, a disorder
CC       characterized by growth retardation, microcephaly, impairment of
CC       nervous system development, pigmentary retinopathy, peculiar facies,
CC       and progeria together with abnormal skin photosensitivity. Cockayne
CC       syndrome dermatological features are milder than those in xeroderma
CC       pigmentosum and skin cancers are not found in affected individuals.
CC       XPF/CS patients, however, present with severe skin phenotypes,
CC       including severe photosensitivity, abnormal skin pigmentation, and skin
CC       cancer predisposition. {ECO:0000269|PubMed:23623389}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Fanconi anemia complementation group Q (FANCQ) [MIM:615272]: A
CC       disorder affecting all bone marrow elements and resulting in anemia,
CC       leukopenia and thrombopenia. It is associated with cardiac, renal and
CC       limb malformations, dermal pigmentary changes, and a predisposition to
CC       the development of malignancies. At the cellular level it is associated
CC       with hypersensitivity to DNA-damaging agents, chromosomal instability
CC       (increased chromosome breakage) and defective DNA repair.
CC       {ECO:0000269|PubMed:23623386, ECO:0000269|PubMed:24027083}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the XPF family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB07689.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/299/XPF";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ercc4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L77890; AAB50174.1; -; Genomic_DNA.
DR   EMBL; AF491814; AAL91593.1; -; Genomic_DNA.
DR   EMBL; AK289726; BAF82415.1; -; mRNA.
DR   EMBL; AC010401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC142631; AAI42632.1; -; mRNA.
DR   EMBL; U64315; AAB07689.1; ALT_INIT; mRNA.
DR   CCDS; CCDS32390.1; -. [Q92889-1]
DR   RefSeq; NP_005227.1; NM_005236.2. [Q92889-1]
DR   PDB; 1Z00; NMR; -; B=834-916.
DR   PDB; 2A1J; X-ray; 2.70 A; A=848-909.
DR   PDB; 2AQ0; NMR; -; A/B=834-916.
DR   PDB; 2KN7; NMR; -; A/D=842-908.
DR   PDB; 2MUT; NMR; -; B=834-916.
DR   PDB; 6SXA; EM; 3.60 A; F=1-916.
DR   PDB; 6SXB; EM; 7.90 A; F=1-916.
DR   PDBsum; 1Z00; -.
DR   PDBsum; 2A1J; -.
DR   PDBsum; 2AQ0; -.
DR   PDBsum; 2KN7; -.
DR   PDBsum; 2MUT; -.
DR   PDBsum; 6SXA; -.
DR   PDBsum; 6SXB; -.
DR   AlphaFoldDB; Q92889; -.
DR   BMRB; Q92889; -.
DR   SMR; Q92889; -.
DR   BioGRID; 108384; 285.
DR   ComplexPortal; CPX-478; ERCC1-XPF endonuclease complex.
DR   CORUM; Q92889; -.
DR   DIP; DIP-42006N; -.
DR   IntAct; Q92889; 29.
DR   MINT; Q92889; -.
DR   STRING; 9606.ENSP00000310520; -.
DR   BindingDB; Q92889; -.
DR   ChEMBL; CHEMBL3883316; -.
DR   iPTMnet; Q92889; -.
DR   MetOSite; Q92889; -.
DR   PhosphoSitePlus; Q92889; -.
DR   BioMuta; ERCC4; -.
DR   DMDM; 229463004; -.
DR   EPD; Q92889; -.
DR   jPOST; Q92889; -.
DR   MassIVE; Q92889; -.
DR   MaxQB; Q92889; -.
DR   PaxDb; Q92889; -.
DR   PeptideAtlas; Q92889; -.
DR   ProteomicsDB; 722; -.
DR   ProteomicsDB; 75575; -. [Q92889-1]
DR   Antibodypedia; 24811; 588 antibodies from 32 providers.
DR   DNASU; 2072; -.
DR   Ensembl; ENST00000311895.8; ENSP00000310520.7; ENSG00000175595.16. [Q92889-1]
DR   Ensembl; ENST00000575156.5; ENSP00000459933.1; ENSG00000175595.16. [Q92889-2]
DR   GeneID; 2072; -.
DR   KEGG; hsa:2072; -.
DR   MANE-Select; ENST00000311895.8; ENSP00000310520.7; NM_005236.3; NP_005227.1.
DR   UCSC; uc002dce.3; human. [Q92889-1]
DR   AGR; HGNC:3436; -.
DR   CTD; 2072; -.
DR   DisGeNET; 2072; -.
DR   GeneCards; ERCC4; -.
DR   GeneReviews; ERCC4; -.
DR   HGNC; HGNC:3436; ERCC4.
DR   HPA; ENSG00000175595; Tissue enhanced (skeletal).
DR   MalaCards; ERCC4; -.
DR   MIM; 133520; gene.
DR   MIM; 278760; phenotype.
DR   MIM; 610965; phenotype.
DR   MIM; 615272; phenotype.
DR   neXtProt; NX_Q92889; -.
DR   OpenTargets; ENSG00000175595; -.
DR   Orphanet; 90321; Cockayne syndrome type 1.
DR   Orphanet; 84; Fanconi anemia.
DR   Orphanet; 910; Xeroderma pigmentosum.
DR   Orphanet; 220295; Xeroderma pigmentosum-Cockayne syndrome complex.
DR   PharmGKB; PA27850; -.
DR   VEuPathDB; HostDB:ENSG00000175595; -.
DR   eggNOG; KOG0442; Eukaryota.
DR   GeneTree; ENSGT00390000004394; -.
DR   HOGENOM; CLU_002265_0_0_1; -.
DR   InParanoid; Q92889; -.
DR   OMA; CVTKKFH; -.
DR   OrthoDB; 277005at2759; -.
DR   PhylomeDB; Q92889; -.
DR   TreeFam; TF101234; -.
DR   PathwayCommons; Q92889; -.
DR   Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA).
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6783310; Fanconi Anemia Pathway.
DR   SignaLink; Q92889; -.
DR   SIGNOR; Q92889; -.
DR   BioGRID-ORCS; 2072; 119 hits in 1164 CRISPR screens.
DR   EvolutionaryTrace; Q92889; -.
DR   GeneWiki; ERCC4; -.
DR   GenomeRNAi; 2072; -.
DR   Pharos; Q92889; Tbio.
DR   PRO; PR:Q92889; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q92889; protein.
DR   Bgee; ENSG00000175595; Expressed in adrenal tissue and 156 other tissues.
DR   ExpressionAtlas; Q92889; baseline and differential.
DR   Genevisible; Q92889; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IDA:UniProtKB.
DR   GO; GO:0070522; C:ERCC4-ERCC1 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0000109; C:nucleotide-excision repair complex; IDA:MGI.
DR   GO; GO:0000110; C:nucleotide-excision repair factor 1 complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IMP:UniProtKB.
DR   GO; GO:0004520; F:DNA endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0000014; F:single-stranded DNA endodeoxyribonuclease activity; IBA:GO_Central.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IMP:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IMP:UniProtKB.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IMP:BHF-UCL.
DR   GO; GO:1905768; P:negative regulation of double-stranded telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:1905765; P:negative regulation of protection from non-homologous end joining at telomere; IMP:BHF-UCL.
DR   GO; GO:0032205; P:negative regulation of telomere maintenance; IMP:UniProtKB.
DR   GO; GO:1904357; P:negative regulation of telomere maintenance via telomere lengthening; IDA:BHF-UCL.
DR   GO; GO:0006289; P:nucleotide-excision repair; IDA:UniProtKB.
DR   GO; GO:1901255; P:nucleotide-excision repair involved in interstrand cross-link repair; IDA:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; IEA:Ensembl.
DR   GO; GO:0000712; P:resolution of meiotic recombination intermediates; IBA:GO_Central.
DR   GO; GO:0009411; P:response to UV; IMP:UniProtKB.
DR   GO; GO:0000723; P:telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0061819; P:telomeric DNA-containing double minutes formation; IMP:BHF-UCL.
DR   GO; GO:0009650; P:UV protection; IEA:Ensembl.
DR   CDD; cd20078; XPF_nuclease_XPF_euk; 1.
DR   Gene3D; 3.40.50.10130; -; 1.
DR   Gene3D; 1.10.150.20; 5' to 3' exonuclease, C-terminal subdomain; 1.
DR   InterPro; IPR006166; ERCC4_domain.
DR   InterPro; IPR011335; Restrct_endonuc-II-like.
DR   InterPro; IPR010994; RuvA_2-like.
DR   InterPro; IPR006167; XPF.
DR   InterPro; IPR047520; XPF_nuclease.
DR   PANTHER; PTHR10150; DNA REPAIR ENDONUCLEASE XPF; 1.
DR   PANTHER; PTHR10150:SF0; DNA REPAIR ENDONUCLEASE XPF; 1.
DR   Pfam; PF02732; ERCC4; 1.
DR   SMART; SM00891; ERCC4; 1.
DR   SUPFAM; SSF52980; Restriction endonuclease-like; 1.
DR   SUPFAM; SSF47781; RuvA domain 2-like; 1.
DR   TIGRFAMs; TIGR00596; rad1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromosome;
KW   Cockayne syndrome; Disease variant; DNA damage; DNA repair; DNA-binding;
KW   Dwarfism; Endonuclease; Fanconi anemia; Hydrolase; Isopeptide bond;
KW   Magnesium; Nuclease; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Ubl conjugation; Xeroderma pigmentosum.
FT   CHAIN           1..916
FT                   /note="DNA repair endonuclease XPF"
FT                   /id="PRO_0000198853"
FT   DOMAIN          683..763
FT                   /note="ERCC4"
FT   REGION          1..457
FT                   /note="Helicase-like"
FT                   /evidence="ECO:0000269|PubMed:16076955"
FT   REGION          233..254
FT                   /note="Leucine-zipper 1"
FT                   /evidence="ECO:0000305|PubMed:8887684"
FT   REGION          270..298
FT                   /note="Leucine-zipper 2"
FT                   /evidence="ECO:0000305|PubMed:8887684"
FT   REGION          460..487
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          502..526
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          658..813
FT                   /note="Nuclease"
FT                   /evidence="ECO:0000269|PubMed:16076955"
FT   REGION          660..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          837..905
FT                   /note="HhH2, dimerization with ERCC1"
FT                   /evidence="ECO:0000269|PubMed:16076955"
FT   MOTIF           486..491
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        511..526
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         289
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZD4"
FT   MOD_RES         764
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QZD4"
FT   MOD_RES         911
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:32034146"
FT   CROSSLNK        500
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         368..372
FT                   /note="ETKKE -> GILWG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056341"
FT   VAR_SEQ         373..916
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056342"
FT   VARIANT         33
FT                   /note="V -> L (in dbSNP:rs34205098)"
FT                   /id="VAR_057477"
FT   VARIANT         150
FT                   /note="R -> C (rare functional variant; causes mild
FT                   disruption of interstrand cross-link repair activity;
FT                   partial loss of protein stability; dbSNP:rs145402255)"
FT                   /evidence="ECO:0000269|PubMed:24027083"
FT                   /id="VAR_072084"
FT   VARIANT         153
FT                   /note="R -> P (in XFEPS; dbSNP:rs121913050)"
FT                   /evidence="ECO:0000269|PubMed:17183314"
FT                   /id="VAR_034802"
FT   VARIANT         168
FT                   /note="A -> V (in dbSNP:rs2020961)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014769"
FT   VARIANT         225
FT                   /note="I -> M (in XP-F; dbSNP:rs764731249)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008200"
FT   VARIANT         230
FT                   /note="L -> P (in FANCQ; dbSNP:rs397509402)"
FT                   /evidence="ECO:0000269|PubMed:23623386"
FT                   /id="VAR_070086"
FT   VARIANT         236
FT                   /note="C -> R (in XPF/CS; dbSNP:rs397509403)"
FT                   /evidence="ECO:0000269|PubMed:23623389"
FT                   /id="VAR_070087"
FT   VARIANT         267
FT                   /note="R -> H (in dbSNP:rs143479220)"
FT                   /evidence="ECO:0000269|PubMed:24027083"
FT                   /id="VAR_072085"
FT   VARIANT         379
FT                   /note="P -> S (in dbSNP:rs1799802)"
FT                   /evidence="ECO:0000269|PubMed:9485007, ECO:0000269|Ref.2"
FT                   /id="VAR_013395"
FT   VARIANT         415
FT                   /note="R -> Q (in dbSNP:rs1800067)"
FT                   /evidence="ECO:0000269|PubMed:10479728,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|Ref.2"
FT                   /id="VAR_013396"
FT   VARIANT         454
FT                   /note="R -> W (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008201"
FT   VARIANT         490
FT                   /note="R -> Q (in XP-F; dbSNP:rs912480692)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008202"
FT   VARIANT         502
FT                   /note="E -> K (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008203"
FT   VARIANT         513
FT                   /note="G -> R (in XP-F; dbSNP:rs769679311)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008204"
FT   VARIANT         529
FT                   /note="I -> T (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008205"
FT   VARIANT         567
FT                   /note="T -> A (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008206"
FT   VARIANT         576
FT                   /note="R -> T (in dbSNP:rs1800068)"
FT                   /evidence="ECO:0000269|PubMed:10479728"
FT                   /id="VAR_013397"
FT   VARIANT         589
FT                   /note="R -> W (in XPF/CS; dbSNP:rs147105770)"
FT                   /evidence="ECO:0000269|PubMed:23623389"
FT                   /id="VAR_070088"
FT   VARIANT         605..611
FT                   /note="Missing (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_008207"
FT   VARIANT         608
FT                   /note="L -> P (in XP-F)"
FT                   /evidence="ECO:0000269|PubMed:9580660"
FT                   /id="VAR_013398"
FT   VARIANT         621
FT                   /note="T -> A (in dbSNP:rs2032331839)"
FT                   /evidence="ECO:0000269|PubMed:24027083"
FT                   /id="VAR_072086"
FT   VARIANT         662
FT                   /note="S -> P (in dbSNP:rs2020955)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014770"
FT   VARIANT         689
FT                   /note="R -> S (in FANCQ; disruption of interstrand
FT                   cross-link repair activity; no effect on protein stability;
FT                   dbSNP:rs149364215)"
FT                   /evidence="ECO:0000269|PubMed:23623386,
FT                   ECO:0000269|PubMed:24027083"
FT                   /id="VAR_070089"
FT   VARIANT         703
FT                   /note="G -> D"
FT                   /evidence="ECO:0000269|PubMed:8797827"
FT                   /id="VAR_005849"
FT   VARIANT         706
FT                   /note="I -> T (in dbSNP:rs1800069)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_014771"
FT   VARIANT         717
FT                   /note="I -> T"
FT                   /evidence="ECO:0000269|PubMed:10479728"
FT                   /id="VAR_013399"
FT   VARIANT         768
FT                   /note="S -> F (in dbSNP:rs12928650)"
FT                   /id="VAR_057478"
FT   VARIANT         786
FT                   /note="S -> F (in FANCQ; disruption of interstrand
FT                   cross-link repair activity; no effect on protein stability;
FT                   dbSNP:rs1451008479)"
FT                   /evidence="ECO:0000269|PubMed:24027083"
FT                   /id="VAR_072087"
FT   VARIANT         799
FT                   /note="R -> W (in XP-F; mild; significant residual repair
FT                   activity; dbSNP:rs121913049)"
FT                   /evidence="ECO:0000269|PubMed:8797827,
FT                   ECO:0000269|PubMed:9579555"
FT                   /id="VAR_005850"
FT   VARIANT         860
FT                   /note="A -> D (in dbSNP:rs4986933)"
FT                   /id="VAR_057479"
FT   VARIANT         873
FT                   /note="I -> V (in dbSNP:rs2020957)"
FT                   /evidence="ECO:0000269|Ref.2"
FT                   /id="VAR_019201"
FT   VARIANT         875
FT                   /note="E -> G (in dbSNP:rs1800124)"
FT                   /evidence="ECO:0000269|PubMed:10479728, ECO:0000269|Ref.2"
FT                   /id="VAR_013408"
FT   VARIANT         912
FT                   /note="G -> E (in dbSNP:rs2020956)"
FT                   /id="VAR_014772"
FT   MUTAGEN         911
FT                   /note="K->Q: Mimics acetylation; promoting interaction with
FT                   ERCC1."
FT                   /evidence="ECO:0000269|PubMed:32034146"
FT   MUTAGEN         911
FT                   /note="K->R: Abolished acetylation by KAT5, leading to
FT                   decreased interaction with ERCC1."
FT                   /evidence="ECO:0000269|PubMed:32034146"
FT   TURN            835..837
FT                   /evidence="ECO:0007829|PDB:2AQ0"
FT   HELIX           839..842
FT                   /evidence="ECO:0007829|PDB:1Z00"
FT   HELIX           850..853
FT                   /evidence="ECO:0007829|PDB:2A1J"
FT   HELIX           860..869
FT                   /evidence="ECO:0007829|PDB:2A1J"
FT   STRAND          870..872
FT                   /evidence="ECO:0007829|PDB:2KN7"
FT   HELIX           873..877
FT                   /evidence="ECO:0007829|PDB:2A1J"
FT   HELIX           881..888
FT                   /evidence="ECO:0007829|PDB:2A1J"
FT   HELIX           891..902
FT                   /evidence="ECO:0007829|PDB:2A1J"
FT   HELIX           905..908
FT                   /evidence="ECO:0007829|PDB:1Z00"
FT   STRAND          911..913
FT                   /evidence="ECO:0007829|PDB:1Z00"
SQ   SEQUENCE   916 AA;  104486 MW;  C58CDE900378CCA8 CRC64;
     MESGQPARRI AMAPLLEYER QLVLELLDTD GLVVCARGLG ADRLLYHFLQ LHCHPACLVL
     VLNTQPAEEE YFINQLKIEG VEHLPRRVTN EITSNSRYEV YTQGGVIFAT SRILVVDFLT
     DRIPSDLITG ILVYRAHRII ESCQEAFILR LFRQKNKRGF IKAFTDNAVA FDTGFCHVER
     VMRNLFVRKL YLWPRFHVAV NSFLEQHKPE VVEIHVSMTP TMLAIQTAIL DILNACLKEL
     KCHNPSLEVE DLSLENAIGK PFDKTIRHYL DPLWHQLGAK TKSLVQDLKI LRTLLQYLSQ
     YDCVTFLNLL ESLRATEKAF GQNSGWLFLD SSTSMFINAR ARVYHLPDAK MSKKEKISEK
     MEIKEGEETK KELVLESNPK WEALTEVLKE IEAENKESEA LGGPGQVLIC ASDDRTCSQL
     RDYITLGAEA FLLRLYRKTF EKDSKAEEVW MKFRKEDSSK RIRKSHKRPK DPQNKERAST
     KERTLKKKKR KLTLTQMVGK PEELEEEGDV EEGYRREISS SPESCPEEIK HEEFDVNLSS
     DAAFGILKEP LTIIHPLLGC SDPYALTRVL HEVEPRYVVL YDAELTFVRQ LEIYRASRPG
     KPLRVYFLIY GGSTEEQRYL TALRKEKEAF EKLIREKASM VVPEEREGRD ETNLDLVRGT
     ASADVSTDTR KAGGQEQNGT QQSIVVDMRE FRSELPSLIH RRGIDIEPVT LEVGDYILTP
     EMCVERKSIS DLIGSLNNGR LYSQCISMSR YYKRPVLLIE FDPSKPFSLT SRGALFQEIS
     SNDISSKLTL LTLHFPRLRI LWCPSPHATA ELFEELKQSK PQPDAATALA ITADSETLPE
     SEKYNPGPQD FLLKMPGVNA KNCRSLMHHV KNIAELAALS QDELTSILGN AANAKQLYDF
     IHTSFAEVVS KGKGKK
//
